<DOC>
	<DOCNO>NCT01579357</DOCNO>
	<brief_summary>The objective pharmacokinetic study exclude possible influence CETUX plasma disposition metabolic activation Capecitabine ( CCB ) regimen give combined Oxaliplatin ( OxPt ) .</brief_summary>
	<brief_title>Pharmacokinetics Metabolic Activation Capecitabine</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion Criteria select : sign write informed consent male female &gt; 18 year Kras wild type adenocarcinoma colon rectum metastatic colorectal carcinoma ECOG &lt; = 2 Exclusion Criteria select : brain metastasis previous chemotherapy stage 3 4 heart failure uncontrolled angina pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>colorectal carcinoma</keyword>
	<keyword>K-ras wild type</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>exclude possible influence CETUX</keyword>
	<keyword>plasma disposition</keyword>
	<keyword>metabolic activation</keyword>
	<keyword>CCB</keyword>
	<keyword>OxPt</keyword>
</DOC>